Antisense Strategy: Biological Utility and Prospects in the Treatment of Hematological Malignancies

References

• Nellen W., Lichtenstein C. What makes an mRNA anti‐sense‐itive?. Trends Bid. Sci. 1993; 18: 419–423
   PubMed Web of Science ®Google Scholar
• Hélène C. Control of oncogene expression by antisenbe nucleic acids. Eur. J. Cancer‐. 1994; 30A: 1721–1726
   PubMed Web of Science ®Google Scholar
• Bock L. C., Griffin L. C., Latham A., Vermaas E. H., Toole J. J. Selection of single‐stranded DNA molecules that bind and inhibit human thrombin. Nature 1992; 355: 564–566
   PubMed Web of Science ®Google Scholar
• Fenster S. D., Wagner R. W., Froehler B. C., Chin D. J. Inhibition of human immunodeficiency virus type I‐env expression by C‐S oligonucleotides specific for Rev response element stem loop. J. Biochemistry 1994; 33: 8391–8398
   Web of Science ®Google Scholar
• Bacon T., Wickstrom E. Daily addition of an anti‐c‐myc DNA oligomer induces granulocytic differentiation or human promyelocytic leukemia HL‐60 cells in both serum‐containing and serum‐free media. Oncogene Res. 1991; 6: 21–32
   PubMedGoogle Scholar
• Daaka Y., Wickstrom E. Target dependence of antisense oligodeoxynucleotide inhibition of c‐Ha‐ras p21 expression and focus formation in T‐24–transformed NIH3T3 cells. Oncogene Res. 1990; 5: 267–275
   PubMedGoogle Scholar
• Chiang M. Y., Chan H., Zounes M. A., Freier S. M., Lima W. F., Bennet C. F. Antisense oligonucleotides inhibit intercellular adhesion molecule I expression by two distinct mechanisms. J. Biol. Chem. 1991; 18162–18171
   PubMed Web of Science ®Google Scholar
• Goodchild J. Antisense inhibitors of gene expression. In Oligodeoxunucleotides, J. Cohen. Macmillan, London 1989; 53–77
   Google Scholar
• Becker D., Meier C., Herlyn M. Proliferation of malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against fibroblast growth factor. EMBO J. 1989; 8: 3685–3691
   PubMed Web of Science ®Google Scholar
• Morrison R. Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes. J. Biol. Chem. 1991; 728–733
   PubMed Web of Science ®Google Scholar
• Rajagopal P., Feigon J. NMR studies of triple‐strand formation from the homopurine‐homopryrimidine deoxyribonucleotides d(GA)h and d(TC)h. J. Biochemistry 1989; 28: 7859–7870
   Web of Science ®Google Scholar
• Radhakrishnan I., Gao X., de los Santos C., Live D., Patel D. J. NMR structural studies of intramolecular (Y+)n (R+)n (Y‐)n DNA triplexes in solution: imino and amino proton and nitrogen markers of GTA base triple formation. J. Biochemistry 1991; 30: 9022–9030
   Web of Science ®Google Scholar
• Cooney M., Czernuszewicz G., Postel E. H., Flint J., Hogan M. E. Site‐specific oligonucleotide binding represses transcription of the human c‐myc gene in vitro. Science 1989; 241: 456–459
   Web of Science ®Google Scholar
• Beal P. A., Dervan P. B. Second structural motif for recognition of DNA by oligonucleotide‐directed triple‐helix formation. Science 1991; 251: 1360–1363
   PubMed Web of Science ®Google Scholar
• Thuong N. T., Hélène C. Sequence‐specific recognition and modification of double‐helical DNA. Angew. Chem. Int. Eng. 1993; 32: 666–690
   Web of Science ®Google Scholar
• Dervan P. B. Reagents for the site‐specific cleavage of megahase DNA. Nature 1992; 359: 87–88
   PubMed Web of Science ®Google Scholar
• Stobel S. A., Doucette‐Stamm L. A., Riba L., Housman D. E., Dervan P. B. Site‐specific cleavage of human chromosome mediated by triple‐helix formation. Science 1991; 254: 1639–1642
   PubMed Web of Science ®Google Scholar
• Pei D., Corey D. R., Schultz P. G. Site‐specific cleavage of duplex DNA by a semisynthetic nuclease via triple‐helix formation. Proc. Natl. Acad. Sci. USA 1990; 87: 9858–9862
   PubMed Web of Science ®Google Scholar
• Strobel S. A., Dervan P. B. Single‐site enzymatic cleavage of yeast genomic DNA mediated by triple helix formation. Nature 1991; 350: 172–174
   PubMed Web of Science ®Google Scholar
• Rothenburg M., Johnson G., Laughlin C., Green I., Cradock J., Sarver N., Cohen J. S. Oligonucleotides as antisense inhibitors of gene expression: therapeutic implications. J. Natl. Cancer Inst. 1989; 81: 1539–1544
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay T., Tainsky M., Cavender C., Roth J. A. Specific inhibition of K‐rus expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 1991; 51: 1744–1748
   PubMed Web of Science ®Google Scholar
• Cameron F. H., Jennings P. A. Specific gene suppression by engineered ribozymes in monkey cells. Proc., Natl. Acad. Sci. USA 1989; 86: 9139–9143
   PubMed Web of Science ®Google Scholar
• Walder R. Y., Walder J. A. Role of RNase H in hybrid‐arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 1988; 85: 5011–5015
   PubMed Web of Science ®Google Scholar
• Woolf T. M., Melton D. A., Jennings C. G. B. Specificity of antisense oligonucleotides in vivo. Proc., Natl. Acad. Sci. USA 1992; 89: 7305–7309
   PubMed Web of Science ®Google Scholar
• Gao W. Y., Han F. S., Storm C., Egan W., Cheng Y. C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for anti‐sense technology. Mol. Pharmacol. 1992; 41: 223–229
   PubMed Web of Science ®Google Scholar
• Cazenave C., Stein C. A., Loreau N., Thuong N. T., Neckers L. M., Subasinghe C., Hélène C., Cohen J. S., Tolmé J. J. Comparitvie inhibition of rabbit globin mRNA translation by modified antisense oligodeoxunucleotides. Nucleic Acids Res. 1989; 17: 4255–4273
   PubMed Web of Science ®Google Scholar
• Ellington A. D., Szostak J. W. In vitro selection of RNA molecules that hind specific ligands. Nature 1990; 346: 818–822
   PubMed Web of Science ®Google Scholar
• Bock L. C., Griffin L. C., Latham J. A., Ve E. H., Toole J. J. Selection of single‐stranded DNA molecules that bind and inhibit human thrombin. Nature 1992; 355: 5634–566
   Web of Science ®Google Scholar
• Yakubov L., Khaled Z., Zhang L. M., Truneh A., Vlassov V., Stein C. A. Oligonucleotides interact with recombinant CD4 at multiple sites. J. Bid. Chem. 1993; 268: 18818–18823
   PubMed Web of Science ®Google Scholar
• Perez J. R., Li Y., Stein C. A., Majumder S., van Oorschot A., Narayanan R. Sequence independent induction of Sp‐1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 1994; 91: 5957–5961
   PubMed Web of Science ®Google Scholar
• Yaniamoto S., Kataoka T., Kuramoto E., Yano O., Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN‐mediated natural killer activity. J. Immunol. 1992; 148: 4072–4076
   PubMed Web of Science ®Google Scholar
• Rathhone M. P., Middlemiss P. J., Gushers J. W., Deforge S., Costello P., Del Maestro R. F. Purine nucleo‐sides and nucleotides stimulate proliferation of a wide range of cell types. In Vitro Cell dev. Biol. 1992; 28A: 529–536
   PubMed Web of Science ®Google Scholar
• Kamano H., Tanaka T., Yamaji Y., Ikeda K., Hata Y., Shiotani T., Ishida T., Takahara I., Iriao S. E. coli gpt gene expression effects in K562 human leukemia cell proliferation and erythroid differentiation altered by mycophenolic acid. Biochem. Int. 1992; 26: 537–543
   PubMedGoogle Scholar
• Stein C. A., Cheng Y. C. Antisense oligonucleotides as therapeutic agents‐Is the bullet really magical?. Science 1993; 261: 1004–1012
   PubMed Web of Science ®Google Scholar
• Carter G., Lemoine N. R. Antisense technology for cancer therapy: does it make sense?. Br. J. Cancer. 1993; 67: 869–876
   PubMed Web of Science ®Google Scholar
• Gao W., Han F., Storm L., Egan W., Cheung Y. Phosphorothioate oligonucleotides are inhibitors for human DNA polymerases and RNAse H: implications for antisense technology. Mol. Pharmacol. 1992; 41: 223–229
   PubMed Web of Science ®Google Scholar
• Tidd D. M., Warenius H. M. Partial protection of oncogene. anti‐sense oligodeoxynucleotides against serum nuclease degradation using terminal methylophosphonate groups. Br. J. Cancer. 1989; 60: 343–350
   PubMed Web of Science ®Google Scholar
• Tidd D. M. Methylphosphonodiester/phosphodiester chimeric oligodeoxynucleotides. Biochem. Soc. Trans. 1992; 20: 746–749
   PubMed Web of Science ®Google Scholar
• Tidd D. M. A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy. Anticancer Res. 1990; 10: 1169–1182
   PubMed Web of Science ®Google Scholar
• Tidd D. M. Synthetic oligonucleotides as therapeutic agents. Br. J. Cancer. 1991; 63: 6–8
   PubMed Web of Science ®Google Scholar
• Agrawal S., Temsamani J., Tang J. Y. Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc., Natl. Acad Sci. 1992; 88: 7595–7599
   Web of Science ®Google Scholar
• O'Brien S. G., Kirkland M. A., Goldman J. M. Antisense therapy for malignant disease. Eur. J. Cancer. 1994; 30A: 1160–1164
   PubMed Web of Science ®Google Scholar
• Loke S. H., Stein C., Zhang X. H., Mori K., Nakanishi M., Subashinghe C., Cohen J. S., Neckers J. M. Characterization of oligonucleotide transport into living cells. Proc. Natl Acad. Sci. 1989; 86: 3476–3478
   Web of Science ®Google Scholar
• Geselowitz D. A., Neckers L. M. Analysis of oligonucleotide binding. internalization. and intracellular trafficking utilizing a novel radiolabeled crosslinker. Antisense Res Devel. 1992; 2: 17–25
   PubMedGoogle Scholar
• Boutarine A. S., Boiziau C., Le Doan T., Toulmé J. J., Hélène C. Effect of the terminal phosphate derivitization of β and α‐oligodeoxynucleotides on their antisense activity in protein biosynthesis. stability and uptake by eukaryotic cells. Biochemie. 1992; 74: 485–489
   PubMed Web of Science ®Google Scholar
• Citro G., Perroti D., Cucco C., D'Agnano I., Sacchi A., Zupi O., Calabretta B. Inhibition of leukaemia cell proliferation by receptor‐mediated uptake of c‐myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 1992; 89: 7031–7035
   PubMed Web of Science ®Google Scholar
• Lasic D. D., Papahadjopoulos D. Liposomes revisited. Science 1995; 267: 1275–1276
   PubMed Web of Science ®Google Scholar
• Chatterjee S., Johnson P. R., Wong K. K. Dual‐target inhibition of HIV‐1 in vitro by means of an adeno‐associated virus antisens vector. Science 1992; 258: 1485–1487
   PubMed Web of Science ®Google Scholar
• Martiat P., Lewalle P., Taj A. S., Philippe M., Larondelle Y., Vaerman J. L., Wildman C., Goldman J. M., Michaux J. L. Retrovirally transduced antisense sequences stably suppress P210BCR‐ABL expression and inhibit the proliferation of BCWABL‐containing cell lines. Blood 1993; 81: 502–509
   PubMed Web of Science ®Google Scholar
• Miller D. Human gene therapy comes of age. Nature 1992; 357: 455–460
   PubMed Web of Science ®Google Scholar
• Gutierrez A. A., Lemoine N. R., Sikora K. Gene therapy of cancer. Lancet 1992; 339: 715–721
   PubMed Web of Science ®Google Scholar
• Calabretta B., Sims R. B., Valtieri M., Caracciolo D., Szczylik C., Venturelli D., Ratajczak M., Beran M., Gewirtz A. M. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c‐myb antisense oligodeoxynucleotides, an in vitro study relevant to bone marrow purging. Proc. Natl. Acad. Sci. USA 1991; 88: 2351–2355
   PubMed Web of Science ®Google Scholar
• Clark S. S., McLaughlin J., Crist W. M., Champlin R., Writte O. N. Unique forms of the ab1 tyrosine kinase distinguish Ph1‐positive CML from Ph1‐positive ALL. Science 1987; 235: 85–88
   PubMed Web of Science ®Google Scholar
• Lugo T. G., Pendergast A. M., Muller A. J., Witte O. N. Tyrosine kinase activity and transformation potency of bcr‐abl oncogene products. Science 1990; 247: 1079–1082
   PubMed Web of Science ®Google Scholar
• Pendergast A. M., Muller A. J., Havlik M. H., Maru Y., Witte O. N. BCR sequences essential for transformation by the BCR‐ABL oncogene bind to the ABL‐SH2 regulatory domain in a non‐phospho‐tyrosine‐dependent manner. Cell 1991; 66: 161–171
   PubMed Web of Science ®Google Scholar
• McLaughlin J., Chianese E., Witte O. N. In vitro transformation of immature hematopoietic cells by the p210 bcdabl oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA 1987; 84: 6558–6562
   PubMed Web of Science ®Google Scholar
• Daley G. Q., Van Etten R. A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830
   PubMed Web of Science ®Google Scholar
• Daley G. Q., Ben‐Neriah Y. Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome‐positive human leukemia. Adv. Cancer Res. 1991; 57: 151–184
   PubMed Web of Science ®Google Scholar
• Voncken J. W., Morris C., Pattengale P., Dennert G., Kikly C., Groffen J., Heisterkamp N. Clonal development and karyotype evolution during leukemogenesis of BCWABL transgenic mice. Blood 1992; 79: 1029–1036
   PubMed Web of Science ®Google Scholar
• Szczylik C., Skorski T., Nicolaides N. C., Manzella L., Malaguarnera L., Venturelli D., Gewirtz A. M., Calabretta B. Selective inhibition of leukemia cell proliferation by bcr‐abl antisense oligodeoxynucleotides. Science 1991; 253: 562–565
   PubMed Web of Science ®Google Scholar
• Skorski T., Nieborowska‐Skorska M., Barletta C., Malaguamera L., Szczylik C., Chen S. T., Lange B., Calabretta B. Highly efficient elimination of Philadelphia1 leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J. Clin. Invest 1993; 92: 194–202
   PubMed Web of Science ®Google Scholar
• De Fabritiis P., Amadori S., Calabretta B., Mandelli F. Elimination of clonogenic Philadelphia‐positive cells using BCR‐ABL antisense oligodeoxynucleotides. Bone marrow transplantation 1993; 12: 261–266
   PubMed Web of Science ®Google Scholar
• Snyder D. S., Wu Y., Wang J. L., Rossi J. J., Swiderski P., Kaplan B. E., Forman S. J. Ribozyme‐mediated inhibition of bcr‐abl gene expression in a Philadelphia chromosome‐positive cell line. Blood 1993; 82: 600–605
   PubMed Web of Science ®Google Scholar
• Skorski T., Szczylik C., Malaguamera L., Calabretta B. Gene‐targeted specific inhibition of chronic myeloid leukemia cell growth by BCR‐ABL antisense oligodeoxynucleotides. Folia Histochemica et Cytobiologica 1991; 29: 85–89
   PubMed Web of Science ®Google Scholar
• Mahon F. X., Belloc F., Reiffers J. Antisense oligomers in chronic myeloid leukemia. Lancet 1993; 341: 566
   PubMed Web of Science ®Google Scholar
• Bishop M. R., Joshi S. S., Jackson J. D., Wu A. G., Sanger W. G., Iversen P. L., Bayever E., Sharp J. G., Zon G., Kessinger A. Purging of peripheral blood progenitor cells with antisense oligonucleotide directed against BCR‐ABL for chronic myelogenous leukemia. Blood 1994; 84(Suppl. 1)740a, abstr. 2946
   Google Scholar
• Smetsers F. C. M., Skorski T., van de Locht L. T. F., Wessels H. M. C., Pennings A. H. M., Witte T., Calabretta B., Mensink E. J. B. M. Antisense BCR‐ABL oligonucleotides induce apoptosis in the Philadelphia chromosome‐positive cell line BV173. Leukemia 1994; 8: 129–140
   PubMed Web of Science ®Google Scholar
• O'Brien S. G., Kirkland M. A., Melo I. V., Rao M. H., Davidson R. J., McDonald C., Goldman J. M. Antisense BCR‐ABL oligomers cause non‐specific inhibition of chronic myeloid leukemia cell lines. Leukemia 1994; 8: 2156–2162
   PubMed Web of Science ®Google Scholar
• Wagner R. W. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994; 372: 333–335
   PubMed Web of Science ®Google Scholar
• Finlay C. A., Hinds P. W., Levine A. J. The p53 proto‐oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083–1093
   PubMed Web of Science ®Google Scholar
• Eliyahu D., Michlovitz D., Eliyahu S., Pinhasi‐Kimhi O., Oren M. Wild‐type p53 can inhibit oncogene‐mediated focus formation. Proc. Natl. Acad. Sci. USA 1989; 86: 8763–8767
   PubMed Web of Science ®Google Scholar
• Diller L., Kassel J., Nelson C. E., Gryka M. A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S. J., Vogelstein B., Friend S. H. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Bid. 1990; 10: 5772–5781
   Web of Science ®Google Scholar
• Chen P. L., Chen Y., Bookstein R., Lee W. H. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250: 1576–1580
   PubMed Web of Science ®Google Scholar
• Bi S., Lanza F., Goldman I. M. The involvement of “tumor suppressor” p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res. 1994; 54: 582–586
   PubMed Web of Science ®Google Scholar
• Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• Nigro J. M., Baker S. J., Preisinger A. C., Jessup J. M., Hostetter R., Clearly K., Bingner S. H., Davison N., Baylin S., Devilee P., Glover T., Collins F. S., Weston A., Modali R., Harris C. C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705–708
   PubMed Web of Science ®Google Scholar
• Gaidano G., Ballerini P., Gong J. Z., Inghirami G., Neri A., Newcomb E. W., Magrath I. T., Knowles D. M., Dalla-Farera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 1991; 88: 5413–5417
   PubMed Web of Science ®Google Scholar
• Parada L., Land H., Weinberg R., Wolf D., Rotter W. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 1984; 312: 649–651
   PubMed Web of Science ®Google Scholar
• Ahuja H., Bar‐Eli M., Advani S. H., Benchimol S., Cline M. J. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc. Natl. Acad. Sci. USA 1989; 86: 6783–6787
   PubMed Web of Science ®Google Scholar
• Mashal R., Shtalrid M., Talpaz M., Kantarjian H., Smith L., Beran M., Cork A., Trujillo J., Gutterman J., Deisseroth A. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 1990; 75: 180–189
   PubMed Web of Science ®Google Scholar
• Sugimoto K., Toyoshima H., Sakai R., Miyagawa K., Hagiwara K., Hirai H., Ishikawa F., Takaku F. Mutations of the p53 gene in lymphoid leukemia. Blood 1991; 77: 1153–1156
   PubMed Web of Science ®Google Scholar
• Slingerland J. M., Minden M. D., Benchimol S. Mutation of the p53 gene in human acute myelogenous leukemia. Blood 1991; 77: 1500–1507
   PubMed Web of Science ®Google Scholar
• Bishop M. R., Bayever E., Iversen P. L., Sharp G., Spinolo J., Zon G., Smith L. J., Ameson M., Ruddon R., Armitage J., Kessinger A. Phase I trial of systemic administration of OL(1)p53 oligonucleotide in refractory acute myelogenous leukemia and advanced myelodysplastic syndrome. Blood 1993; 82(Suppl. 1)443a, abstr. 1757
   Google Scholar
• Coco F. L., Gaidano G., Louie D. C., Offit K., Chaganti R. S. K., Dalla-Favera. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 2289–2295
   PubMed Web of Science ®Google Scholar
• Bayever E., Haines K. M., Iversen P. L. Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk. Lymph. 1994; 12: 223–231
   PubMed Web of Science ®Google Scholar
• Bayever E., Iversen P. Oligonucleotides in the treatment of leukemia. Hematol. Oncol. 1994; 12: 9–14
   PubMed Web of Science ®Google Scholar
• Spinolo J., Iversen P., Smith L., Pirucello S. J., Haines K. M., Norton S. E., Kay H. D., Ameson M. S., Cook P., Zon G., Bayever E. Antisense p53 oligodeoxynucleotide for systemic antileukaemic therapy. Hum. Gene Ther. 1992; 3: 24A
   Google Scholar
• Barton C. M., Lemoine N. R. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br. J. Cancer 1995; 71: 429–437
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay T., Roth J. A codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53. Cancer Res. 1993; 53: 4362–4366
   PubMed Web of Science ®Google Scholar
• Anfossi G., Gewirtz A. M., Calabretta B. An oligomer complementary of c‐myb‐encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc. Natl. Acad. Sci. USA 1989; 82: 3379–3383
   Web of Science ®Google Scholar
• Gewirtz A. M., Calabretta B. A c‐myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 1988; 242: 1303–1306
   PubMed Web of Science ®Google Scholar
• Ratajczak M. Z., Kant J. A., Luger S. M., Hijiya N., Zhang J., Zon G., Gewirtz A. M. In vivo treatment of human leukemia in a scid mouse model with c‐myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 1992; 89: 11823–11827
   PubMed Web of Science ®Google Scholar
• Rabbitts T. H. Chromosomal translocations in human cancer. Nature 1994; 372: 143–149
   PubMed Web of Science ®Google Scholar
• Sentman C. L., Shutter J. R., Hockenberry D., Kanagawa O., Korsmeyer S. J. Bc12 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879–888
   PubMed Web of Science ®Google Scholar
• Strasser A., Harris A. W., Cory S. Bc12 transgene inhibits T‐cell death and perturbs thymic self‐censorship. Cell 1991; 67: 889–899
   PubMed Web of Science ®Google Scholar
• Reed J. C., Cuddy M., Haldar S., Croce C., Nowell P., Makover D., Bradley K. BCL‐2‐mediated tumongenicity of a human T‐lymphoid cell line: synergy with c‐myc and inhibition by BCL‐2 antisense. Proc. Natl. Acad. Sci. USA 1990; 87: 3660–3664
   PubMed Web of Science ®Google Scholar
• Reed J. C., Stein C., Subasinghe C., Haldar S., Croce C., Yum S., Cohen J. Antisense‐mediated inhibition of BCL‐2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phospho‐rothioate oligodeoxynucleotides. Cancer Res. 1990; 50: 6565–6570
   PubMed Web of Science ®Google Scholar
• Pocock C., Al‐Mahdi N., Hall P., Morgan G., Cotter F. In vivo suppression of B‐cell lymphoma with BCL‐2 antisense oligonucleotides. Blood 1993; 82(Suppl. 1)200a, abstr. 784
   Google Scholar
• McManaway M. E., Neckers L. M., Loke S. L., Al‐Nasser A. A., Redner R. L., Shiramizu B. T., Goldschmidts W. L., Huber B. E., Bhatia K., Magrath I. T. Tumor‐specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 1990; 335: 808–811
   PubMed Web of Science ®Google Scholar
• Azuma E., Hiratake S., Nishiguchi Y., Tanaka S., Sakurai M. Successful abrogation of P‐glycoprotein expression of a murine multidrug‐resistant leukemia cell line with anti‐sense MDR oligomer. Blood 1993; 82(Suppl. 1)257a, abstr. 1014
   Google Scholar
• Schlaifer D., Meyer K., Muller C., Attal M., Smith M. T., Tamaki S., Weimels J., Pris J., Jaffrézou J. P., Laurent G., Myers C. E. Antisense inhibition of myeloperoxidase increases the sensitivity of the HL‐60 cell line to vincristine. Leukemia 1994; 8: 289–291
   PubMed Web of Science ®Google Scholar